Case Report

Itolizumab in addressing symptoms of acute respiratory distress syndrome (ARDS) with weaning off oxygen requirements in a COVID-19 patient: A case study

Hemant P Thacker^{1,*}, Amit Dhekane¹, Nivedita Wadhwa¹, Shalaka Patil¹

¹Bhatia Hospital, Mumbai, Maharashtra, India

ARTICLE INFO

Article history:

Received 07-01-2021

Accepted 19-02-2021

Available online 25-02-2021

Keywords:

Acute respiratory distress syndrome
Anti CD6 humanised monoclonal antibody
Cytokines
Cytokine storm
Hyperinflammation
Itolizumab
COVID-19

ABSTRACT

Hyperinflammation and cytokine storm have been reported in severe coronavirus disease (COVID-19) patients. Persistent elevated levels of inflammatory cytokines may lead to an increased risk of vascular hyperpermeability, multiorgan failure, and eventually death over time. Repurposed Itolizumab, a humanized recombinant anti-CD6 monoclonal antibody, is found to inhibit T-cell proliferation and reduce IFN- γ , IL-6, and TNF- α production, thereby leading to reduction in the T-cell infiltration at the sites of inflammation. Here we report a case of a 69 year old COVID-19 confirmed male patient who presented with a history of fever, cough and fatigue. The patient had elevated levels of serum ferritin and CRP. His SpO₂ was 80% and ground glass opacities were observed in his chest X-ray. The patient was initiated on oxygen (using HFR mask) along with best supportive care and saturation was maintained at SpO₂ of 85%. Itolizumab (1.6 mg/kg) was administered as an intravenous infusion (Day 1). On Days 3 and 4, the patient continued on oxygen and maintained a SpO₂ 90% - 92%. On Day 7, there was a 87.86% reduction in the inflammatory marker CRP from baseline. On Day 8, the patient was off oxygen. On Day 9, there was further clinical improvement and the chest x-ray revealed reduction of opacities at the basal and hilar regions. Day 10 showed further CRP reduction of 97.69% from baseline. On Day 12, the patient was discharged. Itolizumab, along with best supportive care, shows potential to reduce hyperinflammation leading to clinical and radiological improvement in COVID-19 patients with severe disease.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Corona Virus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) characterized as a pandemic by the World Health Organization.

Accumulating evidence suggests that immune dysfunction and cytokine dysregulation results in cytokine storm in severe COVID-19 cases.¹⁻³ Persistent elevated levels of inflammatory cytokines may lead to an increased risk of vascular hyperpermeability, multiorgan failure, and eventually death overtime.⁴

CD6 is a co-stimulatory molecule required for optimal T-cell stimulation by the antigen-presenting cells.⁵ The CD6 pathway contributes to Th1 activation and differentiation of T-cells, promoting a proinflammatory response. Itolizumab, a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype, is a selective T-cell co-stimulation modulator that targets the extracellular, scavenger receptor cysteine-rich distal domain 1 of CD6 on T-cells.⁶ It has been found to inhibit T-cell proliferation induced in the presence of ALCAM and excess IL-2 and down regulates the phosphorylation of intracellular proteins implicated in the CD6-mediated activation pathways and reduces IFN- γ , IL-6, and TNF- α production, leading to a reduction in the T-cell infiltration at the sites of inflammation.⁷ However, it does not result in T-regulatory cell depletion.

* Corresponding author.

E-mail address: drhpt@hotmail.com (H. P. Thacker).

Considering the lack of standard treatments for COVID-19, immunomodulatory agents like Itolizumab, used to reduce systemic inflammation, may constitute a possible treatment option. Itolizumab has been approved in India for the treatment of moderate-to-severe psoriasis⁷ and has shown promising results when used in chronic plaque psoriasis,⁸ associated psoriatic arthritis^{9,10} and rheumatoid arthritis.¹¹ In COVID-19 patients, Itolizumab can significantly result in reduction of hyperinflammation by controlling the pro-inflammatory ‘cytokine storm’ syndrome. On 10th July 2020, Drug Controller General of India (DCGI), approved Itolizumab for restricted emergency use in India for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.

An informed consent for publication could not be taken from the patient because of the pandemic situation and constraints in resources and access. However, a no objection certificate was obtained from hospital ethics committee on 9th October, 2020. EC NO: ECR/388/Inst/MH/2013/RR-19. Due efforts were made to conceal information on patient identity.

2. Case Report

Here we report a case of a COVID-19 positive, 69 years old, high risk patient with dual comorbidities of diabetes and hypertension treated with Itolizumab along with best supportive care.

The patient was hospitalized on 22nd May 2020 with a history of fever, cough and fatigue. There was no history of diarrhea, headache, or sore throat. Significant medical history included diabetes and hypertension. The patient was on Metformin 500 mg plus Glimepiride 4 mg twice daily, Amlodipine 5 mg twice daily, Telmisartan 40 mg twice daily and a Statin 20 mg once a day.

On examination, his body temperature was 38.3 °C, blood pressure was 100/70 mmHg, respiratory rate 26/min, FiO₂ rate of 90% and body weight of 68 kg. The patient was positive for SARS-CoV2 infection (RT-PCR). Hematology, liver function tests and serum creatinine were within normal limits. Inflammatory markers, serum ferritin (399.9 ng/ml) and CRP (509.5 mg/L) were elevated. His SpO₂ level was 80% and a chest X-ray revealed ground glass opacities at the basal and hilar regions, suggestive of severe acute respiratory syndrome (Figure 1A). His clinical status score was 5 based on 9-point ordinal scale.¹²

The patient was treated with oxygen (15 L/min) via a high flow rebreathing (HFR) mask along with best supportive care including antipyretics, Vitamin C, Remdesivir, Hydroxychloroquine and Steroids. His oxygen saturation was maintained at 85%. Itolizumab (1.6 mg/kg) was administered as an intravenous infusion on 24th May 2020 (Day 1) for a duration of five to six hours after premedication with Hydrocortisone 100 mg IV, 30 min

prior, and was well tolerated. The patient continued to receive oxygen via HFR mask at the same rate (15 L/min).

On Days 3 and 4 of Itolizumab infusion, the patient continued to be on oxygen via HFR mask (15 L/min) and maintained a SpO₂ 90% - 92%. From Days 5 to 7, the patient improved clinically, was shifted to nasal prong for oxygen (2-4 L/min) and maintained SpO₂ of 92% - 95%. On Day 7, there was a reduction in inflammatory marker CRP from baseline (87.86% reduction). The ordinal scale for clinical improvement score improved to score 4 on Day 5 and remained so until Day 7.

On Day 8, oxygen requirement further reduced, and the patient was off oxygen. On Day 9, there was further clinical improvement and the chest x-ray revealed reduction of opacities at the basal and hilar regions with evidence of healing (Figure 1B). The ordinal scale for clinical improvement score improved to 3 on Day 8 and was at the same level until discharge (day 12). CRP showed significant decrease of 97.69% from baseline to Day 10 (Figure 2). On Day 11, chest x-ray showed signs of healing with fibrosis (Figure 1C).

Over the course of treatment, the clinical improvement correlated well with changes in inflammatory markers and chest X-ray findings. The patient was discharged on 4th June 2020 (Day 12 of Itolizumab administration).

Key laboratory parameters are provided in Table 1.

Fig. 1: Chest X-ray images; (A): On 22nd May 2020 (Upon Hospitalization), (B): On 1st June 2020 (Day 9 post Itolizumab infusion), (C): On 3rd June 2020 (Day 11 post Itolizumab infusion)

3. Discussion

The patient presented at the hospital with a history of fever, cough and fatigue and his medical history included diabetes and hypertension. In agreement with the comprehensive analysis by Yong Hu et al. (2020), hypertension and diabetes are the most prevalent comorbidities and are associated with the severity of COVID-19.¹³ Age, presence of underlying diseases and secondary infections along with low lymphocyte count and elevated serum levels of CRP, D-dimers, ferritin, cardiac troponin and IL-6 are generally considered in risk stratification to predict severe and fatal COVID-19 in hospitalized patients.^{14,15} Elevated CRP is considered as an early marker to predict disease progression and severity. This patient also presented with very high CRP

Table 1: Key laboratory parameters

Date	22/ 05	23/ 05	24/ 05	26/ 05	27/ 05	28/ 05	29/ 05	30/ 05	31/ 05	01/ 06	02/ 06
Day of infusion			Day 1*	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10
Ordinal scale	5	5	5	5	5	4	4	4	3	3	3
FiO2 (%)	90	90	93	93	95	95	95				
SpO2 (%)	80	80	85	90	92	92	95	95			
Mode of Oxygen delivery	HFR Mask	HFR Mask	HFR Mask	HFR Mask	HFR Mask	Nasal prong	Nasal prong	Nasal prong	Room air	Room air	Room air
Oxygen (Litre/ Min)	15	15	15	15	15	2-4	2-4	2-4			
Total leukocyte count (cells/cu.mm)	14400			18870	15780			13370			10970
Platelet count (cells/ cu.mm)	255000			421000	448000			231000			280000
Absolute lymphocyte count (cells/ cu.mm)				566	478			802			1207
Serum creatinine (mg/dl)	3			3	2.60	2.4	2.20	2	1.8		
CRP (mg/mL)	509.5							61.83			11.76

*Day of Itolizumab Infusion

Fig. 2: Change in patient CRP level **Fig. 3:** Change in patient ordinal score from hospitalization to discharge

level of 509.5 mg/ L, which was alarming along with high serum ferritin (399.9ng /ml). After treatment, CRP level showed a significant decline of 87.86% and 97.69% from baseline on day 7 and day 10, respectively. The absolute lymphocyte counts were maintained throughout the duration of hospitalization.

The predominant CT findings of COVID-19 infection are bilateral, peripheral and basal predominant ground-glass opacity, consolidation, or both.^{16,17} As per previous reports, improvement in chest CT is usually seen in 14 day time.¹⁷ In this patient, initial examination of chest X-ray revealed ground glass opacities at the basal and hilar regions which reduced by Day 9 of treatment.

Reported median time for weaning off oxygen therapy was 6 days and it ranged from 2 to 35 days.¹⁸ An improvement of two points on an eight-point ordinal scale was observed and patient was off oxygen on day 8 post treatment (Figure 3). The patient clinically improved and was discharged from the hospital at day 12.

The limitation of this case study is that we could not measure the various other inflammatory markers like IL-6, D-dimer and Ferritin, which could have further added value to these positive clinical and radiological findings. Further research in a clinical trial setting is warranted to validate these findings and analyse efficacy and safety of Itolizumab combined with best supportive in COVID-19 disease.

4. Conclusions

Itolizumab with its differentiated mechanism of action of immunomodulation, along with best supportive care, shows potential to reduce hyperinflammation leading to clinical and radiological improvement in COVID-19 patients with severe disease.

5. Acknowledgement

None.

6. Source of Funding

No financial support was received for the work within this manuscript.

7. Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*. 2020;8(6):e46–7. doi:10.1016/s2213-2600(20)30216-2.
2. Hirano T, Murakami M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. *Immunol*. 2020;52(5):731–3. doi:10.1016/j.immuni.2020.04.003.
3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033–4. doi:10.1016/s0140-6736(20)30628-0.
4. Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. *World J Crit Care Med*. 2019;8(5):59–71. doi:10.5492/wjccm.v8.i5.74.
5. Santos RF, Oliveira L, Carmo AM. Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses. *Curr Drug Targets*. 2016;17(6):630–9. doi:10.2174/1389450116666150531152439.
6. Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. *PLOS ONE*. 2017;12(7):e0180088. doi:10.1371/journal.pone.0180088.
7. Menon R, David BG. Itolizumab-a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. *Clin Cosmet Investig Dermatol*. 2015;8:295.
8. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study. *J Am Acad Dermatol*. 2014;71(3):484–92. doi:10.1016/j.jaad.2014.01.897.
9. Pai G, Pai AH. Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis. *Case Rep Dermatol*. 2017;9(2):141–5. doi:10.1159/000475519.
10. Singh V. Clinical outcome of a novel anti-CD6 biologic itolizumab in patients of psoriasis with comorbid conditions. *Dermatol Res Pract*. 2016;2016:1316326.
11. Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, et al. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. *Clin Exp Immunol*. 2018;191(2):229–39. doi:10.1111/cei.13061.
12. <https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis>. Last accessed 2020on.
13. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Virol*. 2020;127:104371–104371.
14. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J Infect Dis*. 2020;95:304–7. doi:10.1016/j.ijid.2020.04.061.
15. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;46(5):846–8. doi:10.1007/s00134-020-05991-x.
16. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiol*. 2020;295:200463.
17. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19). *Radiol*. 2020;295:715–21.
18. Leulseged TW, Hassen IS, Edo MG, Abebe DS, Maru EH, Zewde WC, et al. Duration of Supplemental Oxygen Requirement and Predictors in Severe COVID-19 Patients in Ethiopia: A Survival Analysis. medRxiv ;doi:10.1101/2020.10.08.20209122.

Author biography

Hemant P Thacker, Consultant Physician & Cardio Metabolic Specialist

Amit Dhekane, Intensive Care Physician

Nivedita Wadhwa, Intensive Care Physician

Shalaka Patil, Intensive Care Physician

Cite this article: Thacker HP, Dhekane A, Wadhwa N, Patil S. Itolizumab in addressing symptoms of acute respiratory distress syndrome (ARDS) with weaning off oxygen requirements in a COVID-19 patient: A case study. *IP Indian J Immunol Respir Med* 2021;6(1):58–61.